Mycoplasma Testing Market Share, Size, Trends, Industry Analysis Report, By Product & Service (Assays, Kits, & Reagents, Instruments, Services); By Technique; By Application; By End User; By Region; Segment Forecast, 2024 - 2032

Mycoplasma Testing Market Share, Size, Trends, Industry Analysis Report, By Product & Service (Assays, Kits, & Reagents, Instruments, Services); By Technique; By Application; By End User; By Region; Segment Forecast, 2024 - 2032

The global mycoplasma testing market size is expected to reach USD 2909.64 Million by 2032, according to a new study by Polaris Market Research. The report “Mycoplasma Testing Market Share, Size, Trends, Industry Analysis Report, By Product & Service (Assays, Kits, & Reagents, Instruments, Services); By Technique; By Application; By End User; By Region; Segment Forecast, 2024 - 2032” gives a detailed insight into current market dynamics and provides analysis on future market growth.

Mycoplasma is a type of bacteria without a cell wall. It is mostly likely to affect the respiratory, urinary, and genital tracts of humans. The presence of stringent regulations and growing concerns about consumer safety is enabling pharmaceutical companies to focus on comprehensive biological testing, including testing of mycoplasma.

A 2023 study published in the Journal of Microbiology focused on exploring advancements in the detection of Mycoplasma genitalium. The recent clearance of molecular-based assays by the U.S. Food and Drug Administration (FDA) permitted diagnostic testing to be widely employed in the United States, making it no longer available only in some laboratories. This is positively influencing the growth of the mycoplasma market.

The emergence of antimicrobial resistance made it difficult to test the presence of mycoplasma in pharmaceutical products and services, which fueled the development of diagnostic tests to determine resistance. Mycoplasma is mostly found in the production phase of biopharmaceutical products, including from the research stage to clinical development, highlighting the need for mycoplasma testing to check safety and accuracy in treating certain diseases.

Do you have any questions? Would you like to request a sample or make an inquiry before purchasing this report? Simply click the link below: https://www.polarismarketresearch.com/industry-analysis/mycoplasma-testing-market/request-for-sample

The growing research innovations in this field and the adoption of advanced technologies are anticipated to promote the expansion of the mycoplasma testing market. For instance, in November 2023, QIAGEN unveiled its three new QIAcuity kits and software update to expand its product line for polymerase chain reaction technology in cell and gene therapies, the food industry, and the pharmaceutical industry.

Ongoing expansion activities by biopharmaceutical companies to enhance the quality and safety of their products are positively influencing the mycoplasma testing market. For instance, in November 2023, Bionique, a pharmaceutical lab specializing in protecting medicines from bacteria, expanded its location at Lake Clear, New York, to meet ongoing demand from rapidly growing cell and gene therapies in the region.

Mycoplasma Testing Market Report Highlights

Assays, Kits, & reagents segment is anticipated to witness the highest growth in the coming years due to the need for ready-to-test kits.

NAT segment accounted for the largest market share owing to its capability to offer faster results.

Cell line testing segment is projected to experience a larger revenue share due to growing biopharmaceutical production.

Asia Pacific is projected to register the fastest growth during the forecast period, attributable to the rising innovations in cell and gene therapies.

The global players include Agilent Technologies, American Type Culture Collection, Biological Industries Israel Beit Haemek Ltd, & Bionique Testing Laboratories, Inc.

Polaris Market Research has segmented the mycoplasma testing market report based on product & service, technique, application, end user and region:

Mycoplasma Testing, Product & Service Outlook (Revenue - USD Million, 2019 - 2032)

Assays, Kits, & Reagents

• NAT assays, kits, & reagents
• ELISA assays, kits, & reagents
• Elimination Kits
• Stains
• Other assays, kits, & reagents

Instruments

Services

Mycoplasma Testing, Technique Outlook (Revenue - USD Million, 2019 - 2032)

NAT

ELISA

Staining

Other technique

Mycoplasma Testing, Application Outlook (Revenue - USD Million, 2019 - 2032)

Cell line testing

Virus Testing

End-of-Production cell testing

Mycoplasma Testing, End User Outlook (Revenue - USD Million, 2019 - 2032)

Pharmaceutical & Biotechnology Companies

Cell Banks & Laboratories

Contract Research Organizations

Academic Research Institutes

Mycoplasma Testing, Regional Outlook (Revenue - USD Million, 2019 - 2032)

North America

• U.S.
• Canada

Europe

• Germany
• UK
• France
• Italy
• Spain
• Russia
• Netherlands

Asia Pacific

• China
• India
• Japan
• South Korea
• Indonesia
• Malaysia

Latin America

• Argentina
• Brazil
• Mexico

Middle East & Africa

• UAE
• Saudi Arabia
• Israel
• South Africa